…Gabriel Mannis, MD Associate Professor of Medicine in the Division of Hematology at Stanford University School of Medicine provides an…
Browsing: Acute Myelogenous Leukemia
By. Naval Daver, MD Date: January 12, 2024 Introducing Naval Daver, a faculty member specializing in MD Anderson Cancers in Houston, Texas.…
By: Parrish Phimes, Date: January 12, 2024 Parrish Phimes, a professor of Intology at the University of Oxford and affiliated with…
By: Pramilla Krishnamurthy, MD Date: January 12, 2024 Pramilla Krishnamurthy, md, a consultant hematologist at King’s College Hospital in London, engaged…
In the interview, Susan Pandya, MD, Vice President of Clinical Development at Servier Pharmaceuticals, discusses the pivotal FDA acceptance and…
Sanam Loghavi is Assistant Professor, Department of Hematopathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center,…
Yasmin Abaza, MD Assistant Professor, Medicine (Hematology and Oncology) In a captivating interview, Yasmin Abaza, MD, an esteemed Assistant Professor of…
Jessica Altman, MD – Professor, Medicine, Hematology Oncology Division; Feinberg School of Medicine Jessica Altman, MD, a dedicated professional at Northwestern…
The discussion focuses on the changing landscape of treatment for mutated acute myeloid leukemia (AML). The speaker emphasizes the significance…
Mark Litzow, MD- Hematologist, Oncologist, Palliative Care Specialist- Mayo Clinic In a presentation delivered by Mark Litzow, MD, the speaker expresses gratitude…
Branko Cuglievan, MD- Assistant Professor, Department of Pediatrics Patient Care, Division of Pediatrics, The University of Texas MD Anderson Cancer…
Marina Konopleva, M.D., Ph.D.- Professor, Department of Oncology (Medical Oncology) Professor, Department of Molecular Pharmacology- Albert Einstein College of Medicine In this presentation…
Tapan Kadia, MD- Professor, Department of Leukemia, Division of Cancer Medicine, M.D. Anderson Cancer Center, Houston, TX In this presentation…
Hetty Carraway, MD- Hematology and Medical Oncology- Cleveland Clinic Hetty Carraway, MD, delivers a comprehensive discussion on immune-based and novel…
Andrew Artz MD- Hematologist-Oncologist- City Of Hope Andrew Artz, MD, expresses gratitude to the organizers and prior presenters, acknowledging the…
Yasmin Abaza, MD Assistant Professor, Medicine (Hematology and Oncology) Yasmin Abaza, MD discusses advancements and challenges in the treatment of Acute…
Naval Daver MD is an Associate Professor in the Department of Leukemia at MD Anderson Cancer Center. Naval Daver, MD expresses…
Brian Andrew Jonas, M.D., Ph.D.- Hematology and Oncology – Hematology and Oncology – UC Davis Comprehensive Cancer Center The presentation…
Jessica Altman, MD – Professor, Medicine, Hematology Oncology Division; Feinberg School of Medicine The presentation discusses various aspects of treatment strategies…
Courtney DiNardo, MD- Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center,…
Eytan M. Stein, MD – Hematologist-Oncologist – Memorial Sloan Kettering Cancer Center Discover the cutting-edge landscape of acute myeloid leukemia…
Alexander Edward Perl, MD, MS – Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania Alexander Edward…
Farhad Ravandi, MD is Janiece and Stephen A. Lasher Professor of Medicine and Chief of Section of Developmental Therapeutics in…
Amir T. Fathi MD Associate Professor of Medicine, Harvard Medical School Program Director, Center for Leukemia- Massachusetts General Hospital Join…
Harry Paul Erba, MD Professor of Medicine Member of the Duke Cancer Institute This content features Harry Paul Erba, MD, who…
Joseph D. Khoury, MD is the Stokes-Shackleford Professor and Chair, Department of Pathology and Microbiology, University of Nebraska Medical Center.…
Sanam Loghavi is Assistant Professor, Department of Hematopathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer…
The panel discussed various aspects related to the use of next-generation sequencing (NGS) and flow cytometry for minimal residual disease…
The panel discussion centered on the optimization of leukemia treatment, particularly focusing on the combination of venetoclax with various therapies.…
The discussion centered on optimizing leukemia treatment strategies through the combination of immunotherapies and chemotherapy. The concern of CNS relapse…
This in-depth discussion among experts explores various facets of leukemia management. The conversation spans topics including challenges in clonotypable patients,…
Medical experts engaged in a discussion about advancing pediatric acute myeloid leukemia (AML) treatment strategies. Venetoclax, a promising drug, was…
Navigating the ever-evolving landscape of leukemia treatment has become an intricate endeavor, with recent clinical trials offering intriguing insights and…
The conversation focuses on AML treatments, including arsenic and another frontline approach. Preventing relapses through non-toxic drugs like masitinib is…
In this discussion, the focus is on optimizing Acute Myeloid Leukemia (AML) treatment. The idea of reducing drug doses upon…
Leading experts engage in a comprehensive discussion on the intricate landscape of long-term remission and resistance patterns in transplanted acute…
Ryan Fitzpatrick, CEO, MD Education In opening the Focus Meeting 2023, Ryan Fitzpatrick, CEO, expresses gratitude to attendees and collaborators…
The discussion revolves around complex topics related to acute myeloid leukemia (AML), including its groups, molecular markers, patient eligibility for…
Joseph D. Khoury, MD is the Stokes-Shackleford Professor and Chair, Department of Pathology and Microbiology, University of Nebraska Medical Center.…
Amir Fathi, MD Associate Professor of Medicine, Harvard Medical School Program Director, Center for Leukemia- Massachusetts General Hospital. Amir Fathi MD, an esteemed professional…
Alexander Edward Perl, MD, MS is a member of the leukemia program in the Abramson Cancer Center of the University…
Courtney D. DiNardo, MD, MSCE Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson…
Eytan M. Stein, MD – Leukemia & Early Drug Development Specialist – David H. Koch Center for Cancer Care at Memorial…
Naval G. Daver, MD is an Associate Professor in the Department of Leukemia at MD Anderson Cancer Center. Naval G.…
Brian Andrew Jonas, MD, Ph.D. Associate Professor of Medicine (Clin X) – UC Davis Comprehensive Cancer Center Brian Jonas MD, Ph.D.…
Marina Konopleva, M.D., Ph.D. Professor, Department of Oncology (Medical Oncology) and Department of Molecular Pharmacology Albert Einstein College of Medicine Jack and…
Farhad Ravandi-Kashani, M.D. Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston,…
Tapan M. Kadia, MD. Professor, Department of Leukemia, Division of Cancer Medicine, M.D. Anderson Cancer Center, Houston, TX Tapan Kadia,…
Anjali Advani, MD – Hematology and Medical Oncology – Cleveland Clinic Meet Anjali Ifani, MD the esteemed Director of the…
Elias Jabbour, MD – Professor, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX This conference…
Anthony Stein, MD, from the City of Hope, has conducted a first-in-human study to evaluate the safety and efficacy of…
Cell Death: Drug Combo Restores Signaling Ability of Leading Treatment for Blood Cancer Christina Glytsou PhD By Christina Glytsou, PhDAssistant…
Allogeneic Hematopoietic Cell Transplantation: How Can the ASAP Trial Help Relapsed or Refractory AML? Johannes Schetelig By Prof. Dr. med.…
Gemtuzumab Ozogamicin Enhances Outcomes in Intermediate Risk AML Patients Receiving Standard Induction Therapy: ASH 2022 Study Results Eunice Wang MD…
iFrame is not supported! Gemtuzumab Ozogamicin Enhances Outcomes in Intermediate Risk AML Patients Receiving Standard Induction Therapy: ASH 2022 Study…
Gemtuzumab Ozogamicin Enhances Outcomes in Intermediate Risk AML Patients Receiving Standard Induction Therapy: ASH 2022 Study Results Eunice Wang MD…
Myelodysplastic Syndromes Treatment Update for 2023 By Deepa Jeyakumar, MD from UCI Health I think what’s very exciting is that…
iFrame is not supported! Inotuzumab and MRD Understanding the Importance of Targeted Therapy in Cancer Treatment Summarized from Van Huynh,…
Myelodysplastic Syndromes Treatment Update for 2023 ASH AML Inotuzumab Update [Slides] – Kiran Naqvi, MD MOASC By Kiran Naqvi, MD…
2023 ASH AML Updates [Slides] – Kiran Naqvi MD – MOASC Acute myeloid leukemia updates from our recent ASH from…
iFrame is not supported! Notable Labs: Thomas Bock ASH 2022 The Future of AML Treatment By Thomas Bock, MD, MBA…
Notable Labs: Thomas Bock ASH 2022 The Future of AML Treatment By Thomas Bock, MD, MBA Where is the blood…
iFrame is not supported! Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician’s Choice…
A new maintenance option is available for AML, but are you proficient in identifying eligible patients? Dr. DiNardo and Dr.…
Yishai Ofran, MD, Director of Hematology department and Shaare Zedek Medical Center Jerusalem speaks about the ASH 2021 Abstract -…
Yishai Ofran, MD, Director of Hematology department and Shaare Zedek Medical Center Jerusalem speaks about the ASH 2021 Abstract -…
Courtney D. DiNardo, MD, MSCE, is a clinical researcher who focuses on prognostication and customized treatments for myeloid malignancies patients…
Courtney D. DiNardo, MD, MSCE, is a clinical researcher who focuses on prognostication and customized treatments for myeloid malignancies patients…
Karuppiah Kannan, Ph.D. Senior Director – Global Program Leader at Takeda Oncology speaks about the ASH 2021 Abstracts – 2488…
Karuppiah Kannan, Ph.D. Senior Director – Global Program Leader at Takeda Oncology speaks about the ASH 2021 Abstracts – 2488…
Naval Daver, MD from The University of Texas MD Anderson Cancer Center speaks about the ASH 2021 Abstract – 3426…
Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician’s Choice of Venetoclax in Combination…
Professor Andrew Wei is a haematologist at the Alfred Hospital and a Victorian Cancer Agency Research Fellow. Andrew has dual…
Professor Andrew Wei is a haematologist at the Alfred Hospital and a Victorian Cancer Agency Research Fellow. Andrew has dual…
Dr. Eunice Wang is the Director of the Roswell Park Comprehensive Cancer Center’s Leukemia Service. Dr. Wang joined the Roswell…
Dr. Eunice Wang is the Director of the Roswell Park Comprehensive Cancer Center’s Leukemia Service. Dr. Wang joined the Roswell…
Pamela J. Sung, MD from the Department of Medicine, Roswell Park Comprehensive Cancer Center speaks about ASH 2021 Abstract -…
Pamela J. Sung, MD from the Department of Medicine, Roswell Park Comprehensive Cancer Center speaks about ASH 2021 Abstract -…
CPI-613 (Devimistat) + Cytarabine + Mitoxantrone in Acute Myeloid Leukemia (AML) FDA Fast Track Designation CPI-613 (Devimistat) Demonstrates Positive Outcomes…
Jean-Jacques Kiladjian, M.D., Ph.D. from Saint-Louis Hospital and Paris Diderot University in France speaks about the ASH abstract – 481…
Eunice S. Wang, MD of Roswell Park Comprehensive Cancer Center discusses the ASH 2020 abstract – 27 Phase 3, Multicenter,…
Anthony S. Stein, MD of the City of Hope speaks about the ASH 2020 abstract – 192 Total Marrow and…
Nicholas J. Short, MD Assistant Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center…
Michael Kelly, MD, MPH, MS, Medical Director at Syros Pharmaceuticals discusses ASH 2020 abstract – 112 SY-1425, a Potent and…
Eunice Wang, MD of Roswell Park Comprehensive Cancer Center Genetic speaks about Testing + AML: New Resource to Bridge the…
Manisha H Shah, MD of The James Ohio State University Comprehensive Cancer Center explains the study: Dabrafenib, Trametinib, and IMRT…
Andrew Wei, MBBS, Ph.D. Alfred Hospital and Monash University U.S. Food and Drug Administration Approves Onureg® (azacitidine tablets), a New…
Andreas Burchert, MD University Hospital Giessen and Marburg Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia…
Christoph Röllig, MD discusses For Acute Myeloid Leukemia, Genetic Testing Is Often Worth the Wait
Keith W. Pratz, MD of Penn Medicine @PennMedicine discusses venetoclax plus azacitidine demonstratesstatistically significant overall survival benefit and improved remission…
Keith W. Pratz, MD of Penn Medicine @PennMedicine discusses venetoclax plus azacitidine demonstratesstatistically significant overall survival benefit and improved remission…
Keith W. Pratz, MD of Penn Medicine @PennMedicine discusses venetoclax plus azacitidine demonstratesstatistically significant overall survival benefit and improved remission…
Daniel Starczynowski, PhD of Cincinnati Children’s Hospital Medical Center @Cincy_Tech Kurome Therapeutics to develop therapies targeting cancer’s ability to evade…
Daniel Starczynowski, PhD of Cincinnati Children’s Hospital Medical Center @Cincy_Tech Kurome Therapeutics to develop therapies targeting cancer’s ability to evade…
Brian Jonas, MD, PhD of UC Davis Comprehensive Cancer Center @UCDavisHealth @ucdavis discusses timing of response to venetoclax combination treatment…
Brian Jonas, MD, PhD of UC Davis Comprehensive Cancer Center @UCDavisHealth @ucdavis discusses timing of response to venetoclax combination treatment…
Brian Jonas, MD, PhD of UC Davis Comprehensive Cancer Center @UCDavisHealth @ucdavis discusses timing of response to venetoclax combination treatment…
Lionel Ades, MD of St. Louis Hospital discusses the phase II study of pevonedistat + azacitidine vs. A in patients…
Lionel Ades, MD of St. Louis Hospital discusses the phase II study of pevonedistat + azacitidine vs. A in patients…
Earn CME: https://www.naccme.com/program/7335-2 In this webcast from the ‘MRD in Hematologic Malignancies: Testing Considerations and Challenges’ symposium, Dr. Gail J.…
Earn CME: https://www.naccme.com/program/19-cpc-101-4 This webcast features a presentation by Dr. Amir T. Fathi on best practices for the integration of…
Earn CME: https://www.naccme.com/program/19-lm-01 In this webcast from the ‘Looking to the Future With Hope: Advances in the Treatment of AML’…
Earn CME: https://www.naccme.com/program/19-lm-01 In this webcast from the ‘Looking to the Future With Hope: Advances in the Treatment of AML’…
Earn CME: https://www.naccme.com/program/19-lm-01 In this webcast from the ‘Looking to the Future With Hope: Advances in the Treatment of AML’…
Constantine Tam, MBBS, MD, Consultant Hematologist, Peter MacCallum Cancer Center, offers his impression of the pivotal clinical data that lead…
Richard Stone, MD, Physician, Hematologic Oncology, Internal Medicine, @DanaFarber shares thoughts on current treatment strategies for elderly acute myeloid leukemia…
Richard Stone, MD, Physician, Hematologic Oncology, Internal Medicine, @DanaFarber elaborates on prognostic factors and the relationship to outcomes in acute…
Richard Stone, MD, Physician, Hematologic Oncology, Internal Medicine, @DanaFarber offers his impression of the landscape for FLT3 inhibition in acute…
Richard Stone, MD, Physician, Hematologic Oncology, Internal Medicine, @DanaFarber provides opinion on whether all acute myeloid leukemia (AML) patients should…
Richard Stone, MD, Physician, Hematologic Oncology, Internal Medicine, @DanaFarber describes the landscape of mutations and targeted therapy in acute myeloid…
Catherine Smith, MD, Assistant Professor, Division of Hematology/Oncology, Department of Medicine, @UCSFCancer discusses the prognostic factors in acute myeloid leukemia…
Catherine Smith, MD, Assistant Professor, Division of Hematology/Oncology, Department of Medicine, @UCSFCancer offers her overall impression on the changing FLT3…
Catherine Smith, MD, Assistant Professor, Division of Hematology/Oncology, Department of Medicine, @UCSFCancer on whether there are emerging mutations in FLT3…
Catherine Smith, MD, Assistant Professor, Division of Hematology/Oncology, Department of Medicine, @UCSFCancer on whether all acute myeloid leukemia (AML) patients…
Catherine Smith, MD, Assistant Professor, Division of Hematology/Oncology, Department of Medicine @UCSFMedicine tells us about the outcomes of the Phase…
Daniel Pollyea, MD, Associate Professor/Clinical Director of Leukemia Services, Division of Hematology, University of Colorado School of Medicine, discusses prognostic…
Daniel Pollyea, MD, Associate Professor/Clinical Director of Leukemia Services, Division of Hematology, University of Colorado School of Medicine, discusses some…
Courtney DiNardo, MD Associate Professor, Department of Leukemia, Division of Cancer Medicine, @MDAndersonNews provides insight on current treatment strategies for…
Courtney DiNardo, MD Associate Professor, Department of Leukemia, Division of Cancer Medicine, @MDAndersonNews describes the targeted therapy landscape in acute…
Courtney DiNardo, MD Associate Professor, Department of Leukemia, Division of Cancer Medicine, @MDAndersonNews explains how the treatment of acute myeloid…
Courtney DiNardo, MD Associate Professor, Department of Leukemia, Division of Cancer Medicine, @MDAndersonNews considers whether intensive chemotherapy should be used…
Saro Armenian, DO, MPH @cityofhope Pediatric Hematologist/Oncologist, Associate Professor, Departments of Pediatrics and Population Sciences, City of Hope Helford Clinical…
Briggs Morrison, MD Chief Executive Officer of @Syndax discusses important details to note in this study. ___________ Syndax Pharmaceuticals, Inc.…
Briggs Morrison, MD Chief Executive Officer of @Syndax answers how likely is this to translate into being beneficial for patients…
Moleculin Biotech, Inc., (Nasdaq:Â MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates…
Briggs Morrison, MD Chief Executive Officer of @Syndax discusses a preclinical study on the activity of menin-MLL inhibition for the…
Results support ongoing Phase 1/2 AUGMENT-101 trial of Syndax Pharmaceuticals’ lead Menin-MLL inhibitor, SNDX-5613, for the treatment of adults with…
Abby Statler, MD of @ClevelandClinic answers if racial disparities in AML are associated with organ dysfunction.
Saro Armenian, DO of @cityofhope discusses the long term morbidity by survivors of AML treated with blood or marrow transplantation.
Aziz Nazha, MD of @CleClinicMD discusses a personalized prediction model to risk stratify patients with AML.
Eunice Wang, MD of @RoswellPark discusses cladribine, cytarabine, granulocyte colony stimulating factor ± mitoxantrone (CLAG ± M) is highly effective…
Responses observed at all dose levels in Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL), including patients with BTK…
No evidence of cardiotoxicity to date; 40% of 10 patients dosed at ≥120 mg/m² demonstrate efficacy; trial progresses in Europe…
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium”) today announced key interim findings from the pivotal Phase 3 SIERRA trial of…
Daniel DeAngelo MD, Institute Physician, Professor of Medicine at Harvard Medical School comments on how myelodysplastic syndrome (MDS) patients who…
Daniel DeAngelo MD, Institute Physician, Professor of Medicine at Harvard Medical School discusses the recent wave of approvals in AML…
Daniel DeAngelo MD, Institute Physician, Professor of Medicine at Harvard Medical School comments on the importance of the updated data…
Daniel DeAngelo MD, Institute Physician, Professor of Medicine at Harvard Medical School elaborates on the phase III study of uproleselan…
Earn CME: https://naccme.com/program/7331 In this presentation from the ‘Looking to the Future With Hope: Advances in the Treatment of AML’…
Earn CME: https://naccme.com/program/7331 In this presentation from the ‘Looking to the Future With Hope: Advances in the Treatment of AML’…
Guillermo Garcia-Manero, MD Of The MD Anderson Cancer Center Discusses Hypomethylating Agents In Myeloid Disorders: Lower Doses Of Decitabine And…
Guillermo Garcia-Manero, MD Of The MD Anderson Cancer Center Discusses Should We Check If The Donor Has A Mutation: Depends…
Dr. Charles Craddock, MD discusses Graft V Host disease when combining Lenalidomide + Azacitidine
Charles Craddock MD PhD @charliecraddock of Queen Elizabeth Hospital discusses the Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in…
Earn CME credit for this activity: https://www.naccme.com/program/2018-802-04 This on-demand webcast examines the latest clinical and pharmacoeconomic data surrounding emerging therapies…
Gary Schiller, M.D. Professor of Medicine Division of Hematology/Oncology At UCLA, Discusses Whats New In AML Transplants. At MOASC Oncology…
Gary Schiller, M.D. Professor of Medicine Division of Hematology/Oncology At UCLA, Discusses Strategies To Treat AML. At MOASC Oncology Summit…
Gary Schiller, M.D. Professor of Medicine Division of Hematology/Oncology At UCLA, Discusses Elaborating On Drug Approvals In AML. At MOASC…
Gary Schiller, M.D. Professor of Medicine Division of Hematology/Oncology At UCLA, Discusses Approaches Seen In AML. At MOASC Oncology Summit…
Deepa Jeyakumar, M.D. Assistant Clinical Professor, Division of Hematology/Oncology At University of California Irvine Discusses Three New Drugs Approved For…
Deepa Jeyakumar, M.D. Assistant Clinical Professor, Division of Hematology/Oncology At University of California Irvine Discusses Dosing Regarding Venetoclax. At MOASC…
Deepa Jeyakumar, M.D. Assistant Clinical Professor, Division of Hematology/Oncology At University of California Irvine Discusses Can Glasdegib Be Used As…
Samer Khaled, MD, Assistant Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, discusses Incorporating Venetoclax Into…
Ravi Vij, MD, Professor of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia, Washington University School of Medicine, discusses Molecular…
John Burke, MD, Hematologist/Oncologist and Associate Chair of the US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, discusses Beat…
John Burke, MD, Hematologist/Oncologist and Associate Chair of the US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, discusses Gilteritinib…
Robert Rifkin, MD, Hematologist/Oncologist, Associate Chair, US Oncology Hematology Research, Rocky Mountain Cancer Centers, discusses The Rationale For Genetically Profiling…
Keith Pratz, MD, Assistant Professor of Oncology, Sidney Kimmel, Comprehensive Cancer Center, Johns Hopkins University, Discusses Phase I Study Of…
Keith Pratz, MD, Assistant Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses Reliability Of The Companion…
James McCloskey, MD, Interim Chief, Division of Leukemia, Hackensack University Medical Center, John Theurer Cancer Center, discusses Molecular Testing In…
John Burke, MD, Hematologist/Oncologist and Associate Chair of the US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, discusses Incorporation…
James McCloskey, MD, Interim Chief, Division of Leukemia, Hackensack University Medical Center, John Theurer Cancer Center, discusses How The FLT3…
Keith Pratz, MD Assistant Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses Emerging Therapies For Newly…
Keith Pratz, MD, Assistant Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses Venetoclax In Treatment Of…
John Burke, MD Hematologist/Oncologist and Associate Chair of the US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, discusses Reliability…
Keith Pratz, MD Assistant Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses How Gilteritinib Fits Into…
James McCloskey, MD Interim Chief, Division of Leukemia, Hackensack University Medical Center, John Theurer Cancer Center, discusses The Role Of…
Samer Khaled, MD Assistant Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope Discusses Treatment Of Acute…
John Burke, MD Hematologist/Oncologist and Associate Chair of the US Oncology Hematology Research Program, Rocky Mountain Cancer Centers Discusses Research…
James McCloskey, MD Interim Chief, Division of Leukemia, Hackensack University Medical Center, John Theurer Cancer Center Discusses Application Of The…
Keith Pratz, MD Assistant Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University Discusses AML Genetic Testing Prior…
Edward Copelan, MD Chair, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute Discusses Gilteritinib For Patients With FLT3+…
Earn CME: https://naccme.com/program/7311 In this presentation from the ‘FLT3 Targets in RIn this presentation from the ‘R AML: Evaluating Emerging…
Earn CME: https://naccme.com/program/7311 In this presentation from the ‘FLT3 Targets in RIn this presentation from the ‘R AML: Evaluating Emerging…
Earn CME: https://naccme.com/program/7311 In this presentation from the ‘FLT3 Targets in AML: Evaluating Emerging Clinical Data and Implications on Current…
Earn CME: https://naccme.com/program/7311 In this presentation from the ‘FLT3 Targets in AML: Evaluating Emerging Clinical Data and Implications on Current…
Charles Craddock, CBE, FRCP(UK), FRCPath, DPhil, of the University of Birmingham, Birmingham, UK, talks about the collective organizational efforts to…
While novel FLT3 inhibitors have been, or will be, approved for use as single agents in the treatment of acute…
Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting, held in Houston, TX, Alexander Perl, MD, of the…
Venetoclax in combination with low intensity chemotherapy for acute myeloid leukemia (AML) in the frontline setting, which although currently under…
Despite benefits of targeted therapies for genetic mutations in AML, a limitation with this approach is that the mutation may…
Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Harry Erba of Duke University, Durham,…
From the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Harry Erba of Duke University, Durham, NC,…
From the 2018 Society of Hematologic Oncology (SOHO) in Houston, TX, Srdan Verstovsek, MD, PhD, from the MD Anderson Cancer…
In this interview, Prof. Srdan Verstovsek, MD, PhD, from the MD Anderson Cancer Center, Houston, TX, suggests that various parameters…
From the 2018 Society of Hematologic Oncology (SOHO) in Houston, TX, Srdan Verstovsek, MD, PhD, from the MD Anderson Cancer…
Myeloproliferative neoplasms, a group of blood disorders, have debilitating effects on patients, including shortening life expectancy and lowering the quality…
Currently, out of all FLT3 inhibitors, only midostaurin is FDA-approved for use in patients with acute myeloid lymphoma (AML). From…
The IDH1 and IDH2 metabolic enzymes are mutated in patients with acute myeloid leukemia (AML), prompting the pharmaceutical development of…
In the last 15 years, there has been a revolution in our understanding of the pathogenesis of acute myeloid lymphoma…
Venetoclax monotherapy has yielded disappointing results in acute myeloid leukemia (AML) because resistance develops along with the propagation of MCL1-expressing…
Alexander Perl, MD, of the University of Pennsylvania, Philadelphia, PA, discusses the effectiveness of drugs currently on the market to…
While venetoclax is widely used in chronic lymphocytic leukemia (CLL) to good effect, previous studies have suggested that the drug…
At the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting, held in Houston, TX, Alexander Perl, MD, of the University…
Christopher Gibson, MD, of Dana-Farber Cancer Institute, Boston, MA, discusses the multiple uses of next-generation sequencing (NGS) in the management…
Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting, held in Houston, TX, Christopher Gibson, MD, of Dana-Farber…
DNA sequencing approaches such as next-generation sequencing (NGS) have been found to be particularly useful when diagnosing cancers. These results…
Christopher Gibson, MD, of Dana-Farber Cancer Institute, Boston, MA, discusses the reliability of next-generation sequencing (NGS) at the 2018 Society…
Florent Malard, MD, PhD, of Saint Antoine Hospital, Paris, France, discusses potential measures to improve the outcome of transplantation at…
Here, Josep-Maria Ribera, MD, PhD, of Germans Trias i Pujol University Hospital, Barcelona, Spain, discusses the potential of measurable residual…
Richard Stone, MD, of the Dana-Farber Cancer Institute, Boston, MA, talks about the latest advances that have been made in…
Antonio Almeida, MD, PhD, of the Instituto Português de Oncologia Francisco Gentil, Lisbon, Portugal, gives an overview of acute myeloid…
Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, of the University of Birmingham, Birmingham, UK, discusses the use of measurable residual…
Alan Burnett, MD, FRCP, of Cardiff University, Cardiff, UK, discusses the use of measurable residual disease (MRD) in acute myeloid…
Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, of the University of Birmingham, Birmingham, UK, discusses the use of targeted vs.…
Alan Burnett, MD, FRCP, of Cardiff University, Cardiff, UK, discusses the antibody-drug conjugate gemtuzumab ozogamicin for acute myeloid leukemia (AML).…
Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Charles Craddock,…
Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, of the University of Birmingham, Birmingham, UK, discusses how we can improve outcomes…
With the recent maturation of novel therapies for acute myeloid leukemia (AML), the field of AML therapeutics is rapidly progressing.…
Dr Fang Liu, of Chengdu Military General Hospital, Chengdu, Sichuan, P.R. China, discusses first-in-human CLL1-CD33 compound CAR T-cells as a…
There has been an influx of novel therapies within the field of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).…
The future of biology is becoming increasingly technologically-based. In this video, Dominique Bonnet, PhD, of the Francis Crick Institute, London,…
In this video, Dominique Bonnet, PhD, of the Francis Crick Institute, London, UK, outlines her group’s research into the biology…
Haematopoietic stem cells give rise to the multitude of blood cells in our circulatory system. In this video, Dominique Bonnet,…
At the 2018 European School of Haematology (ESH) Clinical Updates on Acute Leukaemias, held in Budapest, Hungary, Mark Levis, MD,…
New drugs for acute myeloid leukemia (AML) are constantly being developed. In this video, recorded at the 23rd Congress of…
There has been growing evidence that the combination of hypomethylating agents like azacitidine with immune checkpoint inhibitors could be a…
A large proportion of acute myeloid leukemia (AML) patients are treated by non-specialist community oncologists, who may not have the…
Epigenetic therapies are constantly developing in the field of acute myeloid leukemia (AML). In this video, recorded at the 23rd…
Acute myeloid leukemia (AML) has shown good responses to immunotherapies, including monoclonal antibodies, immune checkpoint inhibitors and bispecific antibodies. Here,…
Speaking from the 23rd Congress of the European Hematological Association (EHA) 2018 in Stockholm, Sweden, Naval Daver, MD, of the…
Andrew Wei, MBBS, PhD, of Monash University, Melbourne, Australia, presented results from the CAVEAT trial (ACTRN12616000445471) at the 23rd Congress…
Clinical trials have demonstrated the positive response rates for FLT3 inhibitors like quizartinib in relapsed FLT3-mutated acute myeloid leukemia (AML).…
Eunice Wang, MD, talks about the role for nivolumab maintenance in high-risk acute myeloid leukemia (AML) patients
Eunice Wang, MD, talks about some of the evolving treatment considerations for FLT3 mutated acute myeloid leukemia (AML) patients who…
Eunice Wang, MD, talks about what we’ve learned about gilteritinib in FLT3-ITD mutated acute myeloid leukemia (AML) patients at the…
The UK is in a leading position internationally for use of minimal residual disease (MRD) measurements in acute myeloid leukemia…
Richard Dillon, MBBS, from King’s College London, UK, discusses the current landscape for minimal residual disease (MRD) in acute myeloid…
Eunice Wang, MD, shares the potential impact of gilteritinib as maintenance therapy after allogenic hematopoietic stem cell transplantation in patients…
Eunice Wang, MD, talks about the impact of next-generation sequencing on treatment selection in acute myeloid leukemia (AML) at Annual…
Cancerous cells in acute myeloid leukemia (AML) utilize different metabolic pathways to normal cells. Using this difference in their biology,…
The treatment of acute myeloid leukemia (AML) patients who have relapsed has, to date, been quite difficult as there has…
Measurable residual disease (MRD) has become a crucial part of treatment planning and prognosis construction in many hematological diseases; however,…
Mark Levis, MD, PhD, talks about new information about gilteritinib in FLT3 mutated acute myeloid leukemia (AML) at Annual Meeting…
Mark Levis, MD, PhD, explains the impact of measurable residual disease in the clinical outcomes of patients with relapsed or…
Mark Levis, MD, PhD, explains the key factors influencing 1st line therapy in acute myeloid leukemia(AML) patients with FLT3 mutations…
Mark Levis, MD, PhD, explains the the impact of next-generation sequencing in AML at Annual Meeting 2018.
Measurable residual disease (MRD) is gaining traction not only as a prognostic indicator, but also as a tool for informing…
Fabio Guolo, MD, of the University of Genoa, Genoa, Italy, spoke to us at the 23rd Congress of the European…
The development of novel agents to treat acute myeloid leukemia (AML) is constantly revolutionizing the field. In this video, Christoph…
Measurable residual disease (MRD) is rising in popularity as a prognostic indicator in a variety of blood cancer types. We…
Esther Oliva, MD, of the Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, Italy, presented preliminary results from her Phase…
Daunorubicin is commonly used to treat acute myeloid leukemia (AML). In this video, Christoph Röllig, MD, of the University Hospital…
In this interview, Mark Levis, MD, PhD, of Sidney Kimmel Comprehensive Cancer Centre, Baltimore, MD, discusses the importantance of involving…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Guillermo Garcia-Manero, MD, of the…
Pracinostat has been shown to be an effective therapy for treating myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) in…
This is a thrilling time for the use of measurable residual disease (MRD) in acute myeloid leukemia (AML), as highlighted…
One big development in clinical trial design in acute myeloid leukemia (AML) is the inclusion of measurable residual disease (MRD)…
There are multiple methodologies for the testing of measurable residual disease (MRD), which each come with various pros and cons,…
One of the major challenges of measurable residual disease (MRD) utilization is the standardization of its measurement and reporting. Here,…